Longeveron Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Wichtige Informationen
25.7%
Wachstumsrate der Gewinne
55.9%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 24.6% |
Wachstumsrate der Einnahmen | 63.3% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 12 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17Longeveron Inc.: A New Approach To Treat Alzheimer's
Oct 09Longeveron spikes after FDA’s Fast Track Designation for lead candidate
Aug 31Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Jul 15Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference
Jul 07Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market
May 06Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth
Apr 03Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses
Feb 15Longeveron: Spooky Social-Media Generated Spike Signifies Nothing
Nov 29Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?
Nov 20Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | N/A | -32 | N/A | N/A | 1 |
12/31/2025 | 1 | -25 | N/A | N/A | 3 |
12/31/2024 | 2 | -21 | N/A | N/A | 2 |
3/31/2024 | 1 | -22 | -17 | -16 | N/A |
12/31/2023 | 1 | -22 | -20 | -19 | N/A |
9/30/2023 | 1 | -21 | -18 | -17 | N/A |
6/30/2023 | 1 | -20 | -18 | -17 | N/A |
3/31/2023 | 1 | -20 | -17 | -16 | N/A |
12/31/2022 | 1 | -19 | -15 | -14 | N/A |
9/30/2022 | 1 | -18 | -15 | -13 | N/A |
6/30/2022 | 1 | -18 | -12 | -11 | N/A |
3/31/2022 | 1 | -17 | -12 | -11 | N/A |
12/31/2021 | 1 | -17 | -11 | -10 | N/A |
9/30/2021 | 2 | -14 | -9 | -9 | N/A |
6/30/2021 | 4 | -10 | -7 | -7 | N/A |
3/31/2021 | 4 | -7 | -5 | -5 | N/A |
12/31/2020 | 6 | -4 | -3 | -2 | N/A |
9/30/2020 | 6 | -3 | -2 | -2 | N/A |
12/31/2019 | 6 | -3 | -3 | -2 | N/A |
12/31/2018 | 2 | -6 | -5 | -5 | N/A |